Worldwide Revenue: $1.26 billion for Q4 2025, up 13% from Q4 2024. US Revenue: $892 million for Q4 2025, an increase of 11% from Q4 2024. International Revenue: $368 million for Q4 2025, up 18% from ...

The accompanying press release dated February 12, 2026 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...

Dexcom is continuing to evolve Stelo beyond basic glucose tracking, announcing a new wave of AI-powered features designed to help users better understand how food and daily habits affect their ...

DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last closing at $66.54 after mixed short term and ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous glucose monitoring system app, leading the FDA to issue its most serious recall notice. A “software defect in ...

The company is presenting several abstracts during the five-day conference showcasing clinical and real-world evidence that support the benefits of its products. Dexcom is presenting several abstracts ...

CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer. Got a confidential news tip? We want to hear ...

July 30 (Reuters) - Dexcom (DXCM.O), opens new tab beat estimates for second-quarter results on Wednesday, driven by strong demand for its continuous glucose monitors, and named Jake Leach as its CEO.

This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know. Taylor Leamey wrote about all ...

DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...

In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...